Wholly Owned Pipeline
PureTech's Wholly Owned Programs are designed to harness immunological and lymphatic system mechanisms for the treatment of lung dysfunction, oncology, lymphatic, neurological and neuropsychological disorders.
Wholly Owned Pipeline
1 | Lymphatic flow disorders, incl. lymphedema | ~1M |
Product candidate for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., IPF, uILDs and Long COVID respiratory complications and related sequelae) and lymphedema.
1 | Long COVID respiratory complications & related sequelae |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | Other fibrotic & inflammatory disorders, such as IPF | ~130K (IPF or uILD) |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-200 is a fully human IgG4 mAb that is designed to block galectin-9, which we are developing for the treatment of solid tumors, including PDAC, CRC and CCA, that do not respond to approved checkpoint inhibitors and have poor survival rates.
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-210 is a fully human IgG1 mAb directed against the δ1 chain of T cells bearing γδT cell receptors (TCRs) we are designing for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Preclinical | Neurological indications |
LYT-300 is an oral form of FDA-approved allopregnanolone, which is currently marketed in the U.S. as ZulressoTM and administrated as a 60-hour intravenous infusion. An oral form of allopregnanolone and other neurosteroids would enable the development of these natural molecules for treating a range of neurological and neuropsychological conditions.
| Phase completed | Phase in progress |
1. Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection.
The BIG Idea - Moving medicine forward at PureTech
